Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy

Human Gene Therapy

Volumn 15, Issue 6, 2004, Pages 597-608

  Stagg, John ^a   Lejeune, Laurence ^a   Paquin, André ^a   Galipeau, Jacques ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CONTROLLED STUDY; DNA MODIFICATION; DOSE RESPONSE; IMMUNE RESPONSE; IMMUNOGENICITY; ISOGRAFT; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; STEM CELL GENE THERAPY; TUMOR GROWTH; ANIMAL; APOPTOSIS; BONE MARROW; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RETROVIRUS; SKIN TUMOR; STROMA CELL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RETROVIRIDAE; SKIN NEOPLASMS; STROMAL CELLS; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 16544369419     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303404323142042     Document Type: Article

References (39)

1. AL-KHALDI, A., ELIOPOULOS, N., MARTINEAU, D., LEJEUNE, L., LACHAPELLE, K., and GALIPEAU, J. (2003). Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neo-angiogenic response in vivo. Gene Ther. 10, 621-629.
2. APOSTOLOU, I., SARUKHAN, A., KLEIN, L., and VON BOEHMER, H. (2002). Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3, 756-763.
3. ARUGA, A., ARUGA, E, and CHANG, A.E. (1997). Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant. Cancer Res. 57, 3230-3237.
4. ASSARSSON, E., KAMBAYASHI, T., SANDBERG, J.K., HONG, S., TANIGUCHI, M., VAN KAER, L., LJUNGGREN, H.G., and CHAMBERS, B.J. (2000). CD8+ T cells acquire NK1.1 and NK cell-associated molecules in vitro and in vivo. J. Immunol. 165, 3673-3679.
5. ATKINS, M.B., KUNKEL, L., SZNOL, M., and ROSENBERG, S.A. (2000). High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6 (Suppl 1):S11-S14.
6. BARTHOLOMEW, A., PATIL, S., MACKAY, A., NELSON, M., BUYANER, D., HARDY, W., MOSCA, J., STURGEON, C., SIATSKAS, M., MAHMUD, N., FERRER, K., DEANS, R., MOSELEY, A., HOFFMAN, R., and DEVINE, S.M. (2001). Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum. Gene Ther. 12, 1527-1551.
7. BARTHOLOMEW, A., STURGEON, C., SIATSKAS, M., FERRER, K., MCINTOSH, K., PATIL, S., HARDY, W., DEVINE, S., UCKER, D., DEANS, R., MOSELEY, A., and HOFFMAN, R. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48.
8. BELLDEGRUN, A., TSO, C.L., ZISMAN, A., NAITOH, J., SAID, J., PANTUCK, A.J., HINKEL, A., DEKERNION, J., and FIGLIN, R. (2001). Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther. 12, 883-892.
9. BOWMAN, L., GROSSMANN, M., RILL, D., BROWN, M., ZHONG, W.Y., ALEXANDER, B., LEIMIG, T., COUSTAN-SMITH, E., CAMPANA, D., JENKINS, J., WOODS, D., KITCHINGMAN, G., VANIN, E., and BRENNER, M. (1998). IL-2 adenovector-transduced autologous tumor cells induce antitumor immune response in patients with neuroblastoma. Blood 92, 1941-1949.
10. BROUARD, N., CHAPEL, A., NEILDEZ-NGUYEN, T.M., GRANOTIER, C., KHAZAAL, I., PEAULT, B., and THIERRY, D. (1998). Transplantation of stromal cells transduced with the human IL3 gene to stimulate hematopoiesis in human fetal bone grafts in non-obese, diabetic-severe combined immunodeficiency mice. Leukemia 12, 1128-1135.
11. CHUAH, M.K., VAN DAMME, A., ZWINNEN, H., GOOVAERTS, .I, VANSLEMBROUCK, V., COLLEN, D., and VANDENDRIESSCHE, T. (2000). Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum. Gene Ther. 11, 729-738.
12. DEANS, R.J., and MOSELEY, A.B. (2000). Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 28, 875-884.
13. DESHMUKH, P., GLICK, R.P., LICHTOR, T., MOSER, R., and COHEN, E.P. (2001). Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice. J. Neurosurg. 94, 287-292.
14. DI NICOLA, M., CARLO-STELLA, C., MAGNI, M., MILANESI, M., LONGONI, P.D., MATTEUCCI, P., GRISANTI, S., and GIANNI, A.M. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843.
15. DJOUAD, F., PIENCE, P., BONY, C., TROPEL, P., APPARAILLY, F., SANY, J., NOEL, D., and JORGENSEN, C. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837-3844.
16. ELIOPOULOS, N., AL-KHALDI, A., CROSATO, M., LACHAPELLE, K., and GALIPEAU, J. (2003). A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmye-loablated, immunocompetent mice. Gene Ther. 10, 478-489.
17. FAKHRAI, H., SHAWLER, D.L., GJERSET, R., NAVIAUX, R.K., KOZIOL, J., ROYSTON, I., and SOBOL, R.E. (1995). Cytokine gene therapy with interleukin-2-transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. 6, 591-601.
18. FEHNIGER, T.A., COOPER, M.A., and CALIGIURI, M.A. (2002). Interleukin-2 and interleukin-15: Immunotherapy for cancer. Cytokine Growth Factor Rev. 13, 169-183.
19. FISHER, K., ANDREESEN, R., and MACKENSEN, A. (2002). An improved flow cytometry assay for the determination of cytotoxic T lymphocyte activity. J. Immunol. Methods 259, 159-169.
20. GALIPEAU, J., LI, H., PAQUIN, A., SICILIA, F., KARPATI, G., and NALBANTOGLU, J. (1999). Vesicular stomatitis virus G pseudo-typed retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res. 59, 2384-2394.
21. HURWITZ, D.R., KIRCHGESSER, M., MERRILL, W., GALANOPOULOS, T., MCGRATH, C.A., EMAMI, S., HANSEN, M., CHERINGTON, V., APPEL, J.M., BIZINKAUSKAS, C.B., BRACKMANN, H.H., LEVINE, P.H., and GREENBERGER, J.S. (1997). Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum. Gene Ther. 8, 137-156.
22. KALISH, R.S., WOOD, J.A., SIEGEL, D.M., KAYE, V.N., and BROOKS, N.A. (1998). Experimental rationale for treatment of high-risk human melanoma with zinc chloride fixative paste: increased resistance to tumor challenge in murine melanoma model. Dermatol. Surg. 24, 1021-1025.
23. KAMBAYASHI, T., ASSARSSON, E., CHAMBERS, B.J., and LJUNGGREN, H.G. (2001). IL-2 down-regulates the expression of TCR and TCR-associated surface molecules on CD8+ T cells. Eur. J. Immunol. 31, 3248-3254.
24. KING, A., GARDNER, L., and LOKE, Y.W. (1999). Co-stimulation of human decidual natural killer cells by interleukin-2 and stromal cells. Hum. Reprod. 14, 656-663.
25. LEHMANN, J., HUEHN, J., DE LA ROSA, M., MASZYNA, F., KRETSCHMER, U., KRENN, V., BRUNNER, M., SCHEFFOLD, A., and HAMANN, A. (2002). Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25-regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 99, 13031-13036.
26. MATHON, N.F., and LLOYD, A.C. (2001). Cell senescence and cancer. Nat. Rev. Cancer 1, 203-213.
27. NAGLER, A., ACKERSTEIN, A., OR, R., NAPARSTEK, E., and SLAVIN, S. (1997). Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 89, 3951-3959.
28. NAGLER, A., ACKERSTEIN, A., BEN-SHAHAR, M., OR, R., NAPARSTEK, E., BEN-YOSEF, R., and SLAVIN, S. (1998). Continuous interleukin-2 infusion combined with cyclophosphamide-based combination chemotherapy in the treatment of hemato-oncological malignancies. Results of a phase I-II study. Acta Haematol. 100, 63-08.
29. PALMER, K., MOORE, J., EVERARD, M., HARRIS, J.D., RODGERS, S., REES, R.C., MURRAY, A.K., MASCARI, R., KIRKWOOD, J., RICHES, P.G., FISHER, C., THOMAS, J.M., HARRIES, M., JOHNSTON, S.R., COLLINS, M.K., and GORE, M.E. (1999). Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. 10, 1261-1268.
30. PALMER, T.D., ROSMAN, G.J., OSBORNE, W.R., and MILLER, A.D. (1991). Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. U.S.A. 88, 1330-1334.
31. PEISTER, A., MELLAD, J.A., LARSON, B.L., HALL, B.M., GIBSON, L.F., and PROCKOP, D.J. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103, 1662-1668.
32. PITTENGER, M.F., MACKAY, A.M., BECK, S.C., JAISWAL, R.K., DOUGLAS, R., MOSCA, J.D., MOORMAN, M.A., SIMONETTI, D.W., CRAIG, S., and MARSHAK, D.R. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147.
33. RAMESH, N., LAU, S., PALMER, T.D., STORB, R., and OSBORNE, W.R. (1993). High-level human adenosine deaminase expression in dog skin fibroblasts is not sustained following transplantation. Hum. Gene Ther. 4, 3-7.
34. ROSENBERG, S.A. (2001). Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250, 462-475.
35. SLIFKA, M.K., PAGARIGAN, R.R., and WHITTON, J.L. (2000). NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J. Immunol. 164, 2009-2015.
36. SOBOL, R.E., SHAWLER, D.L., CARSON, C., VAN BEVEREN, C., MERCOLA, D., FAKHRAI, H., GARRETT, M.A., BARONE, R., GOLDFARB, P., BARTHOLOMEW, R.M., BROSTOFF, S., CARLO, D.J., ROYSTON, I., and GOLD, D.P. (1999). Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A Phase I study. Clin. Cancer Res. 5, 2359-2365.
37. STEWART, A.K., LASSAM, N.J., QUIRT, I.C., BAILEY, D.J., ROTSTEIN, L.E., KRAJDEN, M., DESSUREAULT, S., GALLINGER, S., CAPPE, D., WAN, Y., ADDISON, C.L., MOEN, R.C., GAULDIE, J., and GRAHAM, F.L. (1999). Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial. Gene Ther. 6, 350-363.
38. STUDENY, M., MARINI, F.C., CHAMPLIN, R.E., ZOMPETTA, C., FIDLER, I.J., and ANDREEFF, M. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62, 3603-3608.
39. WANG, J.S., SHUM-TIM, D., GALIPEAU, J., CHEDRAWY, E., ELIOPOULOS, N., and CHIU, R.C. (2000). Marrow stromal cells for cellular cardiomyoplasty: Feasibility and potential clinical advantages. J. Thorac. Cardiovasc. Surg. 120, 999-1005.